Marinomed Biotech AG Announces Dual Market Expansion for Carragelose Products

On April 11, 2024, Marinomed Biotech AG revealed the launch of a new allergen-blocking nasal spray in Austria and its market entry into Mexico with another Carragelose-based product. The Austrian company introduces an innovative solution for hay fever symptoms through its COLDAMARIS Allergie nasal spray, distributed by Sigmapharm. This addition to the Carragelose portfolio aims to provide relief from allergic reactions to grass pollen, enhancing the product range that was primarily focusing on viral infections.

In a strategic move to tap into Latin America's robust pharmaceutical market, Marinomed also announced the availability of its Carragelose nasal spray in Mexico, branded under the name Barlo®. This launch, facilitated by its partner M8 Pharmaceuticals, targets a substantial revenue potential within the region's second largest pharmaceutical market.

Andreas Grassauer, CEO of Marinomed, highlighted the significance of these market expansions not only for diversifying the application of Carragelose products but also for securing year-round sales and exploring new growth avenues. The company's strategy appears focused on enhancing its global footprint and mitigating seasonality effects on its sales.